Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Oxford Lane Capital Corp (OXLC) Price & Performance

ADMA Biologics IncTrade
Oxford Lane Capital CorpTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Oxford Lane Capital Corp — how do they compare? ADMA Biologics Inc trades at $9.87 (market cap $2.22B), while Oxford Lane Capital Corp trades at $9.46 (market cap $909.61M). The key difference: ADMA Biologics Inc is far larger — about 2.4× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 25.76% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.

ADMAOXLC
Market Cap
$2.22B$909.61M
Sector
HealthFinancials
52-Week High
$20.38$18.75
52-Week Low
$7.60$8.15
Enterprise Value
$2.29B
Dividend Yield
25.76%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.

The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.

Oxford Lane Capital Corp

OXLC trades at $9.43, up 1.73% today, with a bullish technical signal from moving averages but mixed oscillators. The stock shows a low P/B of 0.88 but high P/S of 92.8, with recent earnings misses and a volatile net income margin of 100.85% in 2026. Dividends of $0.20 monthly are ongoing, while news highlights NAV discounts and sustainability concerns.

Outlook is cautious due to earnings volatility and high yield risks; opportunities include deep NAV discounts, but risks involve unsustainable distributions and negative ROE/ROA. Analyst consensus is split, with 50% buy ratings reflecting divided sentiment on recovery potential versus financial instability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Oxford Lane Capital Corp

Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.

Read more on OXLC